Jeffrey Meckler Sells 8,000 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) Director Jeffrey Meckler sold 8,000 shares of the stock in a transaction on Monday, May 4th. The shares were sold at an average price of $45.00, for a total transaction of $360,000.00. Following the transaction, the director owned 87,500 shares in the company, valued at $3,937,500. This trade represents a 8.38% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Travere Therapeutics Stock Performance

Shares of NASDAQ:TVTX traded down $0.10 on Wednesday, reaching $44.70. 2,390,035 shares of the company’s stock were exchanged, compared to its average volume of 2,890,153. The firm has a market capitalization of $4.16 billion, a price-to-earnings ratio of -194.33 and a beta of 1.13. Travere Therapeutics, Inc. has a fifty-two week low of $13.88 and a fifty-two week high of $48.61. The business’s 50-day moving average is $32.59 and its two-hundred day moving average is $32.83. The company has a quick ratio of 2.70, a current ratio of 3.13 and a debt-to-equity ratio of 3.16.

Travere Therapeutics (NASDAQ:TVTX) last issued its earnings results on Monday, May 4th. The company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.29. The company had revenue of $127.20 million for the quarter, compared to analysts’ expectations of $136.23 million. Travere Therapeutics had a negative net margin of 4.00% and a negative return on equity of 26.16%. The firm’s revenue was up 55.6% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.47) earnings per share. As a group, equities research analysts forecast that Travere Therapeutics, Inc. will post -0.16 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have weighed in on TVTX. Weiss Ratings reissued a “sell (e+)” rating on shares of Travere Therapeutics in a report on Wednesday, January 21st. Guggenheim increased their target price on shares of Travere Therapeutics from $54.00 to $56.00 and gave the stock a “buy” rating in a report on Friday, April 24th. TD Cowen increased their target price on shares of Travere Therapeutics from $45.00 to $60.00 and gave the stock a “buy” rating in a report on Tuesday. Citigroup increased their target price on shares of Travere Therapeutics from $53.00 to $59.00 and gave the stock a “buy” rating in a report on Tuesday. Finally, Canaccord Genuity Group increased their target price on shares of Travere Therapeutics from $47.00 to $56.00 and gave the stock a “buy” rating in a report on Tuesday, April 14th. Ten research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $47.83.

Key Headlines Impacting Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: TD Cowen raised its price target from $45 to $60 and kept a “buy” rating, implying meaningful upside vs. current levels — a bullish signal from a major sell‑side shop. TD Cowen price target raise
• Positive Sentiment: Wells Fargo upgraded its target to $50 and assigned an “overweight” rating, another near‑term positive catalyst supporting higher valuation expectations. Wells Fargo price target raise
• Neutral Sentiment: HC Wainwright reiterated a “Buy” and $57 target but trimmed FY2027–FY2030 EPS forecasts slightly (e.g., FY2027 cut from $0.71 to $0.60; FY2030 to $4.59 from $4.61). The firm still models substantial multi‑year growth, so this is more of a modest forecast tweak than a change in conviction. HC Wainwright note
• Neutral Sentiment: Earnings call transcript for Q1 2026 is available — recall Travere reported a year‑over‑year revenue gain and an EPS beat in the quarter, which helped underpin recent analyst upgrades. Review the transcript for management commentary on sparsentan commercialization and margin trajectory. Q1 2026 earnings transcript
• Negative Sentiment: Director Roy Baynes sold 9,750 shares (about $431k at the sale price) under a pre‑arranged Rule 10b5‑1 plan. Insider sales can be perceived negatively by the market despite the trading plan disclosure; monitor for any further insider activity. Insider sale filing

Institutional Trading of Travere Therapeutics

Large investors have recently modified their holdings of the company. Emerald Advisers LLC increased its holdings in shares of Travere Therapeutics by 2.6% in the 3rd quarter. Emerald Advisers LLC now owns 2,146,767 shares of the company’s stock worth $51,308,000 after acquiring an additional 55,407 shares during the period. Palisades Investment Partners LLC acquired a new stake in shares of Travere Therapeutics in the 4th quarter worth about $5,264,000. Essex Investment Management Co. LLC acquired a new stake in shares of Travere Therapeutics in the 3rd quarter worth about $3,872,000. Lisanti Capital Growth LLC acquired a new stake in shares of Travere Therapeutics in the 3rd quarter worth about $3,095,000. Finally, Hennion & Walsh Asset Management Inc. increased its stake in Travere Therapeutics by 169.6% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 99,229 shares of the company’s stock valued at $3,792,000 after buying an additional 62,419 shares during the period.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.